Takeda Pharmaceutical (TAK) Total Liabilities (2018 - 2026)

Takeda Pharmaceutical's Total Liabilities history runs 9 years deep, the most recent figure standing at $51.5 billion for Q1 2026.

• On a quarterly basis, Total Liabilities rose 7.51% year-over-year to $51.5 billion in Q1 2026; TTM through Mar 2026 was $51.5 billion, a 7.51% increase from a year earlier, with the FY2026 full-year figure at $53.7 billion, up 11.83% from the prior year.
• Total Liabilities advanced to $51.5 billion in Q1 2026 per TAK's latest filing, from $50.5 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $64.5 billion in Q1 2022 and bottomed at $47.9 billion in Q1 2025.
• The 5-year median for Total Liabilities is $51.9 billion (2022), against an average of $53.6 billion.
• Across the five-year window, Total Liabilities decreased 19.96% in 2022 and increased 7.51% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $51.9 billion in 2022, then fell by 2.44% to $50.6 billion in 2023, then declined by 0.08% to $50.6 billion in 2024, then dropped by 0.22% to $50.5 billion in 2025, then advanced by 2.13% to $51.5 billion in 2026.
• Per Business Quant, the three latest TAK Total Liabilities figures stand at $51.5 billion (Q1 2026), $50.5 billion (Q4 2025), and $49.8 billion (Q3 2025).